On Tuesday, Jefferies, a well-known financial services company, adjusted its outlook on Glaukos Corporation (NYSE: NYSE:GKOS), a player in the ophthalmic medical technology field. The firm increased its price target on the company's shares to $155.00, up from the previous $145.00, while reaffirming its Buy rating on the stock.
The adjustment by Jefferies comes after conducting a proprietary survey of 44 US ophthalmologists, which provided insights into the market acceptance and potential growth of Glaukos' iDose product. The survey findings support Jefferies' belief that there is a healthy demand for iDose and that their forecasts, which are above consensus, are based on conservative assumptions.
According to the analyst at Jefferies, the survey responses indicated a significant opportunity for iDose in the office setting. This could be a key factor in driving the company's growth and justifies the raised price target. The survey also revealed mixed takes on Minimally Invasive Glaucoma Surgeries (MIGS), with expectations that Infinite, another product in the Glaukos portfolio, would grow the fastest across different modalities.
Despite some declines anticipated with iStent W, another of the company's products, the overall outlook for Glaukos remains positive. The potential net share loss is considered modest in light of the opportunities presented by iDose and Infinite. The analyst concluded by reiterating the Buy rating, signaling confidence in the company's stock performance.
In other recent news, Glaukos Corporation has witnessed some significant developments. Truist Securities maintained a Buy rating for the company, emphasizing the potential of its iDose product to boost growth from 2025 onwards. Piper Sandler also kept an Overweight rating, following positive results from Glaukos' Phase 3 trial of Epioxa for treating keratoconus.
The company also reported a 19% increase in second-quarter consolidated net sales, reaching $95.7 million, leading to an upward revision of its full-year 2024 net sales guidance to between $370 and $376 million. This growth was primarily attributed to its US interventional glaucoma franchises, including the iStent portfolio and iDose TR.
Glaukos recently announced the redemption of its outstanding 2.75% Convertible Senior Notes due 2027, with a principal amount of $57.5 million. Meanwhile, BTIG reaffirmed its Buy rating on Glaukos, despite the recent announcement of a partnership between AbbVie (NYSE:ABBV) and Ripple Therapeutics to develop a new drug delivery implant.
Lastly, Glaukos continues to invest in novel technologies, including Epioxa, and expects the adoption of iDose TR to grow in future quarters, facilitated by the J-code, which ensures consistent reimbursement.
InvestingPro Insights
Recent data from InvestingPro adds depth to Jefferies' bullish outlook on Glaukos Corporation (NYSE: GKOS). The company's market capitalization stands at $7.36 billion, reflecting investor confidence in its growth potential. Glaukos has demonstrated impressive revenue growth, with a 15.14% increase over the last twelve months and a notable 19.02% quarterly growth in Q2 2024. This aligns with Jefferies' positive survey findings on iDose demand.
InvestingPro Tips highlight that Glaukos has seen a high return over the last year, with a staggering 98.78% price total return. The stock is currently trading near its 52-week high, with its price at 98.15% of the peak, further supporting Jefferies' optimistic stance. Additionally, Glaukos operates with a moderate level of debt and has liquid assets exceeding short-term obligations, suggesting financial stability as it pursues growth opportunities.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips on Glaukos, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.